![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ARIAD INITIATES PHASE II CLINICAL TRIAL OF AP23573
ARIAD INITIATES PHASE II CLINICAL TRIAL OF AP23573
July 1, 2005
Ariad Pharmaceuticals has announced initiation of enrollment of patients with recurrent or persistent endometrial cancer in a global Phase II clinical trial of its novel mTOR inhibitor, AP23573, as a single agent.
Endometrial cancer is the most common gynecologic malignancy, including ovarian cancer.
This nonrandomized study will evaluate the clinical benefit of AP23573 in well-characterized endometrial cancer patients. Up to approximately 45 patients will be enrolled in the trial at several centers in the U.S. and Europe.
AP23573 will be administered intravenously using a daily dosing regimen. Patients will be followed for at least six months after enrollment but may continue on AP23573 if they have clinical benefit. Data on multiple mTOR-pathway biomarkers, including functional imaging in a subset of patients, will be obtained to help identify patients who are most likely to benefit from treatment with AP23573.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct